Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05632809

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Led by M.D. Anderson Cancer Center · Updated on 2026-03-11

39

Participants Needed

1

Research Sites

259 weeks

Total Duration

On this page

Sponsors

M

M.D. Anderson Cancer Center

Lead Sponsor

N

Nektar Therapeutics

Collaborating Sponsor

AI-Summary

What this Trial Is About

To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.

CONDITIONS

Official Title

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Histologic diagnosis of non-small cell lung cancer
  • Written consent obtained before any study procedures
  • Definitive intent to treat cancer
  • No concurrent cancers except low risk prostate or basal cell skin cancers
  • Previous cancer survivors must be off active treatment for at least 3 months and disease-free for 1 year
  • Adequate liver and kidney function
  • ECOG performance status 0 to 2
Not Eligible

You will not qualify if you...

  • HIV infection, cellular immune deficiencies, or hereditary/congenital immunodeficiencies
  • Prior hepatitis B or C diagnosis without sustained virologic response
  • History of autoimmune disease, Crohn's disease, ulcerative colitis, or inflammatory disease
  • Serious active infections needing treatment
  • Known or suspected allergy to study drugs
  • Recurrent radiation at treatment site
  • Major surgery within 4 weeks without recovery
  • Other conditions or therapies that risk participant safety or study results
  • Previous study enrollment
  • Pregnancy or positive pregnancy test in women of childbearing potential
  • Prior treatment with anti-PD-1 or anti-PD-L1 antibodies
  • Leukemias or lymphomas rich in T or NK cells
  • Significant interstitial lung disease or unresolved pneumonitis above grade 1 after chemoradiation
  • Unresolved grade 4 toxicities from chemoradiation
  • Prior exposure to IL-2 or IL-5

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

S

Steven H. Lin, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here